Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023
April 19, 2023 08:05 ET
|
Indaptus Therapeutics
NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...
Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
April 17, 2023 08:00 ET
|
Indaptus Therapeutics
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today...
Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
March 15, 2023 08:05 ET
|
Indaptus Therapeutics
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...